Longitudinal timepoint assessment of patient-reported clinical disease activity in ulcerative colitis and Crohn’s disease: suitability of a rapid Patient-Reported Outcome 2 (PRO-2) assessment
Abstract
Background & Aims: Patient-reported outcomes (PRO) are essential for monitoring disease activity and treatment response in inflammatory bowel disease (IBD). The conventional PRO-2 requires several days of prospective symptom recording, increasing participant burden and attrition in longitudinal research. We evaluated whether a “rapid PRO-2”, using 2 days of data collected retrospectively and prospectively in a single day, could serve as a reliable and pragmatic alternative to a 4-day PRO-2.
Methods: Using data from the ongoing IBD-RESPONSE cohort (n = 684 Crohn’s disease [CD]; n = 548 ulcerative colitis [UC]), we compared 4-day PRO-2 and rapid PRO-2 scores at baseline and 14 weeks post-therapy to assess disease activity, clinical (non) response and remission.
Results: At baseline, 87.1% (596/684) of CD and 88.7% (486/548) of UC patients remained in the same active/inactive disease activity category (Cohen’s kappa: CD 0.715; UC 0.762; both P < .001). At week 14, 77% (CD; 195/252) and 83.1% (UC; 193/232) remained in the same non-response/response/remission category (Cohen’s kappa: CD 0.653; UC 0.743; both P < .001). Discrepancies mainly involved adjacent category shifts (ie, between response and remission, or non-response and response), with minimal re-classification between remission and non-response (n = 7 CD and n = 2 UC). Greater symptom variability across the 4 days increased the likelihood of switching between remission and non-response (odds ratio [95% confidence interval], CD 5.0 [3.65–6.85]; UC 7.8 [5.6–11.0], both P < .001). Responsiveness to clinical change was comparable between instruments.
Conclusions: The rapid PRO-2 retains essential symptom data and demonstrates strong agreement with the 4-day PRO-2, offering an alternative in longitudinal studies to minimize burden and attrition.
Related
- Predicting subsequent-year physical fitness assessment failure in university students using longitudinal data and explainable machine learning
- Outcome Stratification in Non-ST-Segment Elevation Myocardial Infarction: Standardized Assessment of Left Ventricular Global Longitudinal Strain
- Risk assessment and prediction of myopia among school-age children in South China: protocol for a longitudinal follow-up study
- Does internalized homonegativity lower sexual satisfaction? A longitudinal assessment among gay, bisexual and other men who have sex with men (GBM) in Canada's three largest cities
- Polygenic risk score assessment of LDL-Cholesterol levels and progression to severe hypercholesterolemia and statin treatment; a longitudinal study from a large middle eastern biobank
BibTeX
@article{beck2026longitudinal,
title = {{Longitudinal timepoint assessment of patient-reported clinical disease activity in ulcerative colitis and Crohn’s disease: suitability of a rapid Patient-Reported Outcome 2 (PRO-2) assessment}},
author = {Lauren C Beck and Gregory R Young and Nicola J Wyatt and Robert J Mulligan and Robert D Lees and Chaonan Dong and Hannah Watson and Trevor Liddle and Ally Speight and Dean M Allerton and Victoria Hildreth and Naomi S McGregor and Ruth Wood and Mary Doona and Debbie Alexander and Samantha Baillie and Biljana Brezina and Beatriz Camesella Perez and Bessie Cipriano and Jessica Cordle and Dominic Devine and Alexander T Elford and Kay Goulden and Marie Green and Hannah Husband and Lorna Ingoe and Lauren John and Sunita Dias Juliao and Andrew King and Klaartje Kok and Yasmin Laidler and Isabel Laszczak and Sarah Lawrence and Irish Lee and Melanie Love and Julian Marchesi and Claire McQuillian and Helen Millage and Ibinye Minimah and Alison Moss and Felicia Onoviran and Christopher Palmer-Jones and Gareth C Parkes and Sally Payton and Jahleesha Pinney and Kiran Prabhu and Chandni Radia and Parizade Raymode and Juan de la Revilla Negro and Francesca Rosa and Lydia Scarlett and Mohammed T Sharip and Natalie Shields and Sreedhar Subramanian and Robert Varley and Busiswa Vuyelele-Titchmarsh and Valentina Toska and Kevin Whelan and Kate Wistance and Mark Yongco},
journal = {Journal of Crohn's \& colitis},
year = {2026},
month = oct,
doi = {10.1093/ecco-jcc/jjag153},
url = {https://europepmc.org/article/PMC/PMC13730273},
note = {CC BY},
}
RIS
TY - JOUR
TI - Longitudinal timepoint assessment of patient-reported clinical disease activity in ulcerative colitis and Crohn’s disease: suitability of a rapid Patient-Reported Outcome 2 (PRO-2) assessment
AU - Lauren C Beck
AU - Gregory R Young
AU - Nicola J Wyatt
AU - Robert J Mulligan
AU - Robert D Lees
AU - Chaonan Dong
AU - Hannah Watson
AU - Trevor Liddle
AU - Ally Speight
AU - Dean M Allerton
AU - Victoria Hildreth
AU - Naomi S McGregor
AU - Ruth Wood
AU - Mary Doona
AU - Debbie Alexander
AU - Samantha Baillie
AU - Biljana Brezina
AU - Beatriz Camesella Perez
AU - Bessie Cipriano
AU - Jessica Cordle
AU - Dominic Devine
AU - Alexander T Elford
AU - Kay Goulden
AU - Marie Green
AU - Hannah Husband
AU - Lorna Ingoe
AU - Lauren John
AU - Sunita Dias Juliao
AU - Andrew King
AU - Klaartje Kok
AU - Yasmin Laidler
AU - Isabel Laszczak
AU - Sarah Lawrence
AU - Irish Lee
AU - Melanie Love
AU - Julian Marchesi
AU - Claire McQuillian
AU - Helen Millage
AU - Ibinye Minimah
AU - Alison Moss
AU - Felicia Onoviran
AU - Christopher Palmer-Jones
AU - Gareth C Parkes
AU - Sally Payton
AU - Jahleesha Pinney
AU - Kiran Prabhu
AU - Chandni Radia
AU - Parizade Raymode
AU - Juan de la Revilla Negro
AU - Francesca Rosa
AU - Lydia Scarlett
AU - Mohammed T Sharip
AU - Natalie Shields
AU - Sreedhar Subramanian
AU - Robert Varley
AU - Busiswa Vuyelele-Titchmarsh
AU - Valentina Toska
AU - Kevin Whelan
AU - Kate Wistance
AU - Mark Yongco
PY - 2026
DA - 2026/10/01
JO - Journal of Crohn's & colitis
DO - 10.1093/ecco-jcc/jjag153
UR - https://europepmc.org/article/PMC/PMC13730273
AB - Background & Aims: Patient-reported outcomes (PRO) are essential for monitoring disease activity and treatment response in inflammatory bowel disease (IBD). The conventional PRO-2 requires several days of prospective symptom recording, increasing participant burden and attrition in longitudinal research. We evaluated whether a “rapid PRO-2”, using 2 days of data collected retrospectively and prospectively in a single day, could serve as a reliable and pragmatic alternative to a 4-day PRO-2. Methods: Using data from the ongoing IBD-RESPONSE cohort (n = 684 Crohn’s disease [CD]; n = 548 ulcerative colitis [UC]), we compared 4-day PRO-2 and rapid PRO-2 scores at baseline and 14 weeks post-therapy to assess disease activity, clinical (non) response and remission. Results: At baseline, 87.1% (596/684) of CD and 88.7% (486/548) of UC patients remained in the same active/inactive disease activity category (Cohen’s kappa: CD 0.715; UC 0.762; both P < .001). At week 14, 77% (CD; 195/252) and 83.1% (UC; 193/232) remained in the same non-response/response/remission category (Cohen’s kappa: CD 0.653; UC 0.743; both P < .001). Discrepancies mainly involved adjacent category shifts (ie, between response and remission, or non-response and response), with minimal re-classification between remission and non-response (n = 7 CD and n = 2 UC). Greater symptom variability across the 4 days increased the likelihood of switching between remission and non-response (odds ratio [95% confidence interval], CD 5.0 [3.65–6.85]; UC 7.8 [5.6–11.0], both P < .001). Responsiveness to clinical change was comparable between instruments. Conclusions: The rapid PRO-2 retains essential symptom data and demonstrates strong agreement with the 4-day PRO-2, offering an alternative in longitudinal studies to minimize burden and attrition.
SN - 1873-9946
SN - 1876-4479
ER -